All In Biotech

Drug Trial Radar · NCT01402882

Clinical Randomisation of an Antifibrinolytic in Significant Head Injury

Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: an International Randomised, Double Blind Placebo Controlled Trial

Last checked: Nov 19, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 12,737 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,737

Actual

Start

Jul 2012

Primary completion

Oct 2019

Study completion Oct 2019

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CRASH-3 trial will provide reliable evidence about the effect of tranexamic acid on mortality and disability in patients with traumatic brain injury. The effect of tranexamic acid on the risk of vascular occlusive events and seizures will also be assessed. Additionally, a nested study will be conducted in a subset of CRASH-3 trial participants. This nested study (CRASH-3 Intracranial Bleeding Sub-Study \[CRASH-3 IBS\]) will examine the effect of tranexamic acid on intracranial haemorrhage and cerebral ischaemia using CT Scans in approximately 1,000 patients randomised into the CRASH-3 trial.

Conditions

  • Traumatic Brain Injury

Interventions

  • Tranexamic AcidDrug

    2 grams (1 gram over 10 minutes and 1 gram over 8 hours)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary outcome is death in hospital in patients recruited within 3 hours and cause of death will be described.Time frame: within 28 days of injury

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • High Technology Medical Center, University Clinic

    Tbilisi, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.